Latest Conference Articles

Up to 91% patients who received maximum dosage of the drug achieved a triglyceride level of <150 mg/dL, according to new data presented at ESC 2020.

A look at how asymptomatic AFib is being combatted by consumer devices and embraced, large-scale population research.

New cohort analyses show very few patients with atrial fibrillation exercise regularly or rigorously—which could be a detriment to their mortality risk.

Daniel Gaudet, MD, PhD, discusses what's next in clinical pursuits of the greatly underdiagnosed hereditary cardiovascular disease.

Investigators simulated baseline CV risk and predicted potential risk reduction among a cohort of evolocumab users across Europe.

A podcast interview with the president of American Society of Preventive Cardiology, on the eve of the ESC 2020 Congress.

PCSK9 inhibitor therapy within 24 hours after PCI was shown to bring LDL-C levels down closer to guideline-recommended goals.

Patients with IPF and multiple comorbidities experienced similar effects from nintedanib to those with few or no comorbidities.

In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

A perspective on what's moved virtually, and what hasn't, since the pandemic began in March.

An interview with a Cleveland Clinic investigator on adjusting macular edema screening methods.

Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.

A total of 115 of 200 examined eyes had some form of diabetic retinopathy in data presented at the ASRS 2020 virtual meeting.

Patients demonstrate visual gains from baseline but mean visual acuity worsens between 2 and 5 years.

In research presented at ASRS 2020, investigators found 56% of patients with PDR had a DME code, with a sensitivity of 85%.

A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.

The findings support treating eyes with the condition before they progress to proliferative diabetic retinopathy.

The specialty is on the precipice of advancement. What gets it over the hurdle?

In a study presented at ASRS 2020, investigators find an improvement in DRSS is not correlated with a change in best corrected visual acuity.

Using the 4 JAMA benchmarks, investigators do not find any online articles that are entirely accurate and accountable.

The findings of the study highlight the importance of screening eye exams from index diagnosis.

Steroids are often prescribed for diabetic macular edema following ineffectiveness of laser photocoagulation and anti-VEGF.

The findings demonstrate the importance of providers to manage diabetes, diabetic retinopathy, and mental illness comorbidities.

A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.

Top websites for macular degeneration content do not necessarily have better quality information or readability.

In data presented virtually during the ASRS 2020 meeting, investigators find X-82 is non inferior in visual acuity outcomes.

The addition of oral zeaxanthin reduces the risk of subfoveal choroidal neovascularization development compared to previously published studies.